Nadezhda V. Izmozherova

Nadezhda V. Izmozherova

Auto-generated profile, based on publicly available information

Nadezhda V. Izmozherova

Ural State Medical University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2022 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
NIN. V. Izmozherova
N. V. Izmozherova
APA. A. Popov
A. A. Popov
AKA. A. Kuryndina
A. A. Kuryndina
EGE. I. Gavrilova
E. I. Gavrilova
MSM. A. Shambatov
M. A. Shambatov
VBV. M. Bakhtin
V. M. Bakhtin
Aim. Assessment of the level and structure of polymorbidity, features of pharmacotherapy therapy in patients of different age groups, belonging to the category of high and extremely high cardiovascular risk, observed in outpatient clinics.Material and methods. The single-stage study included 282 patients of high and very high cardiovascular risk who were divided into three groups: (1) age 45-59 years, (2) 60-74 years, (3) ≥75 years. The structure of polymorbidity and features of pharmacotherapy in different age groups patients were evaluated. The frequency of polypragmasia was determined, and treatment adequacy in patients over 65 years of age was analyzed using the STOPP / START criteria and the Beers criteria of 2019.Results. High and very high cardiovascular risk patients have been found to be highly polymorbid, polimorbidity level increasing with age. Thus, among elderly patients, ischemic heart disease, chronic heart failure (CHF) were more often detected, as well as a high frequency of concomitant and background conditions, especially bone and joint system involvement (osteoarthritis, rheumatoid arthritis). Polypragmasia (administration of ≥5 drugs) was detected in 150 patients (53.2%) and was more common among elderly patients. According to Beers criteria, there were 48 cases of inadequate medication prescribing in 46 (28.0%) elderly patients. According to 80 STOPP criteria, 75 cases of prescribing potentially non-recommended drugs to 55 patients (32.1%) were detected. According to 34 START criteria, 116 cases of non-prescribing of necessary drugs to 52 (30.4%) elderly patients were found. When assessing the frequency of prognosis modifying medication prescribing, patients with CHF in 107 (63.0%) cases received angiotensin converting enzyme inhibitors, and in 42 cases (24.5%) angiotensin II receptor antagonists had been prescribed. Thus, 87.5% CHF patients were receiving renin-angiotensin-aldosterone system blockers. Statins were administered in 225 (79.8%) cases, antiplatelet agents were pre-scribed in 157 (67.9%) cases, and 23 persons (9.9%) were on oral anticoagulants for atrial fibrillation.Conclusion. In the structure of the studied cohort most of the high and very high cardiovascular risk outpatients were polimorbid, elderly and senile. Polypragmasia has been detected in more than half of elderly outpatients (53%), irrational medication was found in 28% to 30% elderly patients. Most patients with CHF were on statins, antithrombotic therapy, and renin-angiotensin-aldosterone system blockers.

5 December 2021 in Ural Medical Journal
Verified
Journal Article
Open access
PDF file
NIN. V. Izmozherova
N. V. Izmozherova
APA. A. Popov
A. A. Popov
ATA. I. Tsvetkov
A. I. Tsvetkov
MSM. A. Shambatov
M. A. Shambatov
IAIrina Petriona Antropova
Irina Petriona Antropova
VIV. E. Ispavsky
V. E. Ispavsky
Introduction. Acute respiratory distress syndrome (ARDS) and cardiovascular events, acute myocardial injury being the most frequent of the latter, are among the leading causes of death in COVID-19 patients. The lack of consensus on acute myocardial injury pathogenesis mechanisms, the patients management, treatment an rehabilitation logistics, the anticoagulant treatment in identified SARS-CoV-2 or suspected COVID-19 patients setting indicates the need to assess, analyze and summarize the available data on the issue.Materials and methods. Scientific publications search was carried out in PubMed, Google Scholar databases for the period from December 2019 to September 2021.Results and Discussion. Cardiospecific troponin I increase beyond reference limits is reported to occur in at least every tenth patient with identified SARS-CoV-2, the elevated troponin detection rate increasing among persons with moderate to severe course of the infection. The mechanisms of acute myocardial injury in patients with COVID-19 are poorly understood. By September 2021, there are several pathogenesis theories. A high frequency viral myocarditis direct cardiomyocytes damage is explained by the high SARS-CoV-2 affinity to ACE2 expressed in the myocardium. The cytokine storm related myocardial damage is reported a multiple organ failure consequence. Coagulopathy may also trigger myocardial microvessels damage. Up to every third death of SARS-CoV-2 infected persons is related to the acute myocardial injury. At the same time, due to the high incidence of the acute myocardial injury, it is rather difficult to assess the true incidence of acute myocardial infarction in patients with COVID-19. In the pandemic setting, the waiting time for medical care increases, the population, trying to reduce social contacts, is less likely to seek medical help. In this regard, in order to provide effective medical care to patients with acute myocardial infarction, it is necessary to develop algorithms for providing care adapted to the current epidemiological situation.Conclusion. The treatment of patients with probable development of acute myocardial damage against the background of new coronavirus infection should be performed in accordance with the current clinical guidelines. Anticoagulant therapy should be administered in a prophylactic dose under control of hemostasis parameters and a wide range of biochemical parameters.

27 June 2023 in ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia»
Verified
Journal Article
Open access
PDF file
НИНадежда Владимировна Изможерова
Надежда Владимировна Изможерова
АПАртем Анатольевич Попов
Артем Анатольевич Попов
IAIrina Petriona Antropova
Irina Petriona Antropova
ЛКЛеонид Игоревич Кадников
Леонид Игоревич Кадников
ВИВладислав Евгеньевич Испавский
Владислав Евгеньевич Испавский
ДСДмитрий Викторович Салов
Дмитрий Викторович Салов
В обзоре анализируются современные представления о структурно-функциональных особенностях интегринов у человека; исследования связи между полиморфизмом гена T1565C, кодирующего интегрин бета‑3 (ITGβ3), тромботических явлений и эффективностью применяемых антитромбоцитарных препаратов; рассмотрена целесообразность исследования на наличие данного полиморфизма. Анализ проведен на основе публикаций, представленных в базах данных и web-ресурсах: MEDLINE, PubMed, Google Scholar, Cyberleninka, электронной библиотеке eLibrary, охватывающих временной период с 1989 по 2022 г. Критериями включения в обзор являлись статьи на русском и английском языках, результаты когортных и рандомизированных исследований, мета-анализов, систематические обзоры исследуемой проблемы, а также описания клинических случаев. Критериями исключения из выборки послужили исследования с отсутствием четко сформулированных выводов или наличием противоречивых результатов. This review describes the main modern provisions on the structural and functional features of integrins in humans; studies of the relationship between polymorphism of the T1565C gene encoding integrin beta 3 (ITGβ3), thrombotic events and the effectiveness of antiplatelet drugs used; the expediency of research for the presence of this polymorhism is considered. Data analysis was carried out on the basis of publications presented in databases and web resources: MEDLINE, PubMed, Google Scholar, Cyberleninka, eLibrary, covering the time period from 1989 to 2022. The inclusion criteria for the review were articles in Russian and English, results of cohort and randomized studies, meta-analyses, systematic reviews of the problem under study, as well as descriptions of clinical cases. Exclusion criteria were studies with no clear-cut conclusions or conflicting results.

17 November 2023 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
NINadezhda V. Izmozherova
Nadezhda V. Izmozherova
APArtem A. Popov
Artem A. Popov
ATAndrey I. Tsvetkov
Andrey I. Tsvetkov
LKLeonid I. Kadnikov
Leonid I. Kadnikov
VIVladislav E. Ispavskii
Vladislav E. Ispavskii
ЦИЦветков Андрей Игоревич
Цветков Андрей Игоревич
Background: Cardiovascular complications of COVID-19 result in challenges for differential diagnosis, patients referral and treatment, which negatively affect the outcomes. Aim: To identify clinical particulars of various types acute coronary syndrome course in patients with COVID-19. Materials and methods: This retrospective cross-sectional study included 202 patients with COVID-19 and acute coronary syndrome (ACS) admitted to a primary vascular medicine center from September to December 2020. Their medical records were used for the analysis of ACS and COVID-19 clinical course, including physical and history data, laboratory and instrumental work-up. For the analysis, the patient sampling was divided into three study groups: 50 patients with unstable angina (UA), 107 patients with acute myocardial infarction with ST segment elevation (STEMI), and 45 patients with acute myocardial infarction without ST segment elevation (non-STEMI). Results: There were no differences in clinical manifestations of ACS in the study groups. As far as clinical manifestations of coronavirus infections are concerned, the patients differed significantly as per prevalence of fever and dry cough. Fever was present in 22 (44%) UA patients, 18 (17%) of STEMI patients and in 10 (22%) of non-STEMI patients (p 0.001 for comparison of 3 groups, Kruskall-Wallis test), whereas dry cough was present in 18 (36%), 19 (18%), and 14 (31%) patients, respectively (p = 0.029). Paired comparison (Mann-Whitney test with Bonferroni adjustment) showed significant differences between US and STEMI groups for both symptoms. The number of involved vessels (median [25%; 75%]) in UA patients was 0 [0; 2], in STEMI and non-STEMI patients 2 [1; 3] (p 0.001). A left coronary artery stenosis was detected in 2 (6%) of the UA patients, 13 (14%) of the STEMI and 4 (13%) of the non-STEMI patients (p = 0.452); left anterior descending artery stenosis, in 12 (36%), 67 (72%) and 23 (72%) patients, respectively (p 0.001). In the pairwise comparison, there were differences between UA and STEMI groups and between UA and non-STEMI groups. A left circumflex artery stenosis was found in 7 (21%) of the UA patients, 45 (48%) of the STEMI and 18 (56%) of the non-STEMI patients (p = 0.008); the pairwise comparisons showed the difference between UA and non-STEMI study groups. A right coronary artery stenosis was identified in 9 (27%), 64 (69%) and 18 (56%) of the study patients, respectively (p 0.001); in the pairwise comparison the difference was found between the UA and STEMI group. There were significant differences in the percentage of the right descendent and right coronary artery stenosis: the right descending artery stenosis was 70% [45; 80] in the UA patients, 90% [70; 100] in the STEMI and 95% [70; 100] in the non-STEMI patients (p = 0.013), whereas the right coronary artery stenosis was 50% [45; 80], 90% [70; 100], 90% [60; 100], respectively (p = 0.018). In the pairwise comparison, the differences were found between the UA and STEMI patients in both arteries. The STEMI patients had higher TIMI thrombus grade scores than those with non-STEMI: 3 [0; 5] vs 0 [0; 4] (p = 0.023). The rates of successful percutaneous coronary intervention and achievement of TIMI flow grade 3 between them was not significantly different (p = 0.170). Conclusion: The ACS patients with ACS and COVID-19 have high thrombotic load according to coronary angiography and TIMI score in the case of STEMI and more frequent absence of hemodynamically significant stenosis in those with UA and non-STEMI. The absence of any difference in clinical manifestations of ACS and viral infection between the study groups (except fever and dry cough difference between the UA and STEMI patients) indicates that specific characteristics of the ACS course in COVID-19 patients can be identified only by coronaroangiography.

21 March 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
GAG. P. Arutyunov
G. P. Arutyunov
ETE. I. Tarlovskaya
E. I. Tarlovskaya
AAAlexander Arutyunov
Alexander Arutyunov
TBT. I. Batluk
T. I. Batluk
NKN. A. Koziolova
N. A. Koziolova
ЯХЯ. Б. Ховаева
Я. Б. Ховаева
Aim. To investigate the prevalence and characteristics of polyvascular disease in the Eurasian region's population with one or more previously established locations of atherosclerotic arterial damage, and to evaluate the diagnostic importance of the ankle-brachial index (ABI) as a marker for polyvascular disease (PVD).Material and methods. A total of 1837 patients were included in the main branch of the KAMMA registry (patients with PVD), among which 91,6% had coronary artery disease (CAD) (n=1683). For further analysis, the group of patients with CAD was combined with 1222 patients included in the second branch of the registry — KAMMA-cardio, forming a patient population (n=2905), in which all patients had verified CAD. The mean age of patients was 66,0 [59,0; 72,0] years, with 60,3% being male. Peripheral arteries was assessed using ultrasound examination.Results. PVD was present in 95,6% of patients with coronary atherosclerosis: dual-region involvement was observed in 51,3% of patients, three-region involvement in 37,1%, four-region involvement in 3,4%, and five-region involvement in 2,0%. Stenoses of the common carotid artery were observed in 71% of patients, internal carotid artery — in 68%, lower limb artery — in 52%, and renal and mesenteric artery — in 8,3%. There were following diagnostic effectiveness of the ABI for detecting patients with lower limb artery stenosis was: sensitivity — 58,0%, specificity — 83,6%. The quality of antithrombotic and lipid-lowering therapy was insufficient.Conclusion. In the overwhelming majority (95,6%) of patients with CAD in the KAMMA registry, PVD was revealed, with nearly half of the patients having involvement in three or more arterial zones. In the patient population with CAD, there should be an active effort to identify patients with PVD, using at least the ABI determination and active modern antithrombotic and lipid-lowering therapy according to current clinical guidelines.

1 July 2021 in EDULEARN Proceedings
Verified
Conference Paper
Closed access
PDF file
LVLyudmila Voronina
Lyudmila Voronina
EZEkaterina Zaitseva
Ekaterina Zaitseva
EGElena Gaisina
Elena Gaisina
NINadezhda Izmozherova
Nadezhda Izmozherova
Information about the paper titled "PERSONNEL POTENTIAL OF TEACHERS OF RUSSIAN UNIVERSITIES IN THE CONDITIONS OF DIGITALIZATION" at IATED Digital Library